ask the EMA oracle [Outliers]

posted by Ohlbe – France, 2011-10-06 18:31 (4749 d 18:21 ago) – Posting: # 7436
Views: 8,470

Dear D. Labes,

❝ A little bit curious for me is the underlined sentence. Taken literally it would not allow to exclude such profiles for the Test formulation :confused:.


My understanding is that this is precisely the idea ! Basically, if no concentration is measured after the reference product, EU regulators are ready to assume that the subject did not swallow the product. The reference formulation is considered to be reliable :-|
If the same situation happens after the test product, they consider that they cannot make the difference between a non-compliant subject and a deficient tablet. They will not take any chance.

Regards
Ohlbe

Regards
Ohlbe

Complete thread:

UA Flag
Activity
 Admin contact
23,247 posts in 4,885 threads, 1,652 registered users;
67 visitors (0 registered, 67 guests [including 11 identified bots]).
Forum time: 12:52 CEST (Europe/Vienna)

The real struggle is not between the right and the left
but between the party of the thoughtful
and the party of the jerks.    Jimmy Wales

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5